Last C$0.09 CAD
Change Today 0.00 / 0.00%
Volume 0.0
GES On Other Exchanges
Symbol
Exchange
Venture
Frankfurt
As of 5:00 PM 05/27/14 All times are local (Market data is delayed by at least 15 minutes).

gemoscan canada inc (GES) Snapshot

Open
--
Previous Close
C$0.09
Day High
--
Day Low
--
52 Week High
04/2/14 - C$0.10
52 Week Low
04/25/14 - C$0.06
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
38.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GEMOSCAN CANADA INC (GES)

Related News

No related news articles were found.

gemoscan canada inc (GES) Related Businessweek News

No Related Businessweek News Found

gemoscan canada inc (GES) Details

Gemoscan Canada, Inc. develops, owns, and markets food sensitivity and dietary management solutions for consumers in Canada. Its solutions include HEMOCODE food intolerance system, a personalized naturopathic nutritional program that promotes well-being. This system also provides personalized dietary guidelines and replacement food suggestions. The company commercializes its food intolerance management solution directly to consumers in partnership with retailers. Gemoscan Canada, Inc. was founded in 2003 and is headquartered in Toronto, Canada.

Founded in 2003

gemoscan canada inc (GES) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$240.6K
Chief Financial Officer and Secretary
Total Annual Compensation: C$44.1K
Compensation as of Fiscal Year 2013.

gemoscan canada inc (GES) Key Developments

Gemoscan Canada, Inc. Reports Operational and Financial Results for the First Quarter Ended June 30, 2014

Gemoscan Canada, Inc. reported operational and financial results for the first quarter ended June 30, 2014. For the three months ended June 30, 2014, total revenues were CAD 675,621, representing an increase of approximately 81% from CAD 373,894, versus the comparative three-month period in fiscal 2014. For the three months ended June 30, 2014 the Company posted a net loss for the quarter of CAD 268,866. The loss represents an increase of approximately 14% from the comparative-period loss of CAD 235,446. This loss stemmed primarily from weaker than expected clinic performance during the period, compounded by higher service, marketing, and general and administrative costs for the quarter. The company further reported an increase to cash used for operating activities for the three months ended June 30, 2014, of CAD 165,702 versus CAD 146,944, for the comparative period in fiscal 2014; driven primarily by the net loss for the current period.

Gemoscan Canada, Inc. Reports Operational and Financial Results for the Fourth Quarter and Twelve Months Ended March 31, 2014

Gemoscan Canada, Inc. reported operational and financial results for the fourth quarter and twelve months ended March 31, 2014. For the twelve months ended March 31, 2013, total revenues were CAD 2,655,313 representing an increase of approximately 146% from CAD 1,078,294, versus the comparative twelve-month period in fiscal 2013. For the twelve months ended March 31, 2013 the Company posted a net loss for the year of CAD 1,269,477. The loss is a reduction of 37% from the comparative-period loss of CAD 2,004,014. The company further reported a reduction to cash used for operating activities for the 12 months ended March 31, 2013, of CAD 316,271 versus CAD 1,079,592 for the comparative period in fiscal 2013. Fiscal fourth quarter revenues of CAD 703,049, were also better, representing a 305% increase over CAD 172,174, for the comparative three-month period in fiscal 2013. Similarly, a reduced fiscal fourth quarter loss of CAD 376,722 was also reported, versus CAD 640,147 for the comparative period in fiscal 2013, equaling a reduction in loss of approximately 70%.

Gemoscan Canada, Inc. Auditor Raises 'Going Concern' Doubt

Gemoscan Canada, Inc. filed its Annual on Jul 31, 2014 for the period ending Mar 31, 2014. In this report its auditor, Zeifman & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GES:CN C$0.09 CAD 0.00

GES Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GES.
View Industry Companies
 

Industry Analysis

GES

Industry Average

Valuation GES Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GEMOSCAN CANADA INC, please visit www.hemocode.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.